From: Post-translational modifications on the retinoblastoma protein
Cell lines/tissues | Conditions | Ubiquitination sites detected by MS | References |
---|---|---|---|
MMTV-Tg (LINK-A) mouse mammary gland tumour | Untreated | K803 | [35] |
HEK293T cells; MV4–11 cells | Unperturbed (for HEK293T cells); proteasome inhibitor MG132 treatment (for MV4–11 cells) | K810 | [51] |
Jurkat E6-1 cells | Unperturbed | K63, K65, K265, K279, K289, K319, K329, K359, K420, K640, K791, K810, K814, K844, K847, K870, K896, K900 | [52] |
U2OS cells | UV treated | K842 | [53] |
HEK293T cells | UV treated | K97, K823, K842, K846, K856, K879 | [54] |
Hep2 and Jurkat cells | Treatment with proteasome inhibitors bortezomid and b-AP15 | K63, K65, K94, K136, K143, K265, K279, K289, K327, K341, K420, K427, K432, K537, K640, K791, K810, K814, K824, K847, K870, K896, K900 (in Jurkat cells) K63, K65, K94, K136, K143, K265, K279, K289, K327, K341, K420, K427, K537, K640, K810, K847, K860, K870, K896, K900 (in Hep2 cells) | [55] |
HCT116 cells | Combined treatment with bortezomid and cycloheximide | K143 | [56] |